Bristol-Myers Squibb said that the U.S. Food and Drug Administration (FDA) has accepted for filing and priority review a supplemental biologics license application (sBLA) for Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. The FDA previously granted Opdivo breakthrough therapy designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received prio...